A Randomized, Controlled, Evaluator-blinded, Multi-center, Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2018
At a glance
- Drugs LYS-228 (Primary)
- Indications Urinary tract infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 24 Oct 2018 Status changed from recruiting to discontinued
- 21 Aug 2018 Planned End Date changed from 29 Jul 2019 to 28 Oct 2019.
- 21 Aug 2018 Planned primary completion date changed from 29 Jul 2019 to 28 Oct 2019.